Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.51 |
| ▸ | NEU4 | Q8WWR8 | 1/20 | 0.40 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.40 |
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.40 |
| ▸ | SIGLEC7 | Q9Y286 | 7/20 | 0.39 |
| ▸ | CD22 | P20273 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15087683 | 0.92 | NANP (0.55) | NANPNEU4NEU3NEU2SIGLEC7 | |
| SCHEMBL31225703 | 0.88 | NANP (0.53) | NANPSIGLEC7CD22 | |
| SCHEMBL17057676 | 0.84 | NANP (0.69) | NANPNEU4NEU3NEU2SIGLEC7 | |
| SCHEMBL16362511 | 0.82 | NANP (0.55) | NANPNEU4NEU3NEU2SIGLEC7 | |
| SCHEMBL18357291 | 0.82 | NANP (0.55) | NANPNEU4NEU3NEU2SIGLEC7 | |
| SCHEMBL15090335 | 0.82 | NANP (0.55) | NANPNEU4NEU3NEU2SIGLEC7 | |
| SCHEMBL16839998 | 0.82 | NANP (0.55) | NANPNEU4NEU3NEU2SIGLEC7 | |
| SCHEMBL15087689 | 0.82 | NANP (0.55) | NANPNEU4NEU3NEU2SIGLEC7 | |
| SCHEMBL31225768 | 0.80 | NANP (0.43) | NANPCD22 | |
| SCHEMBL31225646 | 0.79 | NANP (0.33) | NANP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | NANP 503/4885NEU4 42/4885NEU3 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.